Illinois is currently home to 2628 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571
Recruiting
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
NCT06807424
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Clinic of Robert Hozman, Skokie, Illinois
Conditions: Arthritis, Psoriatic
Register for Updates
A Study to Evaluate the Safety and Tolerability of Eravacycline in Children Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
NCT06794541
Recruiting
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in children aged 8 to \<18 years with cIAI.
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
04/03/2025
Locations: Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Complicated Intra-abdominal Infections (cIAI)
Register for Updates
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
NCT06676072
Recruiting
The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024
Recruiting
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/03/2025
Locations: EmVenio Research, Chicago, Illinois
Conditions: Seasonal Influenza
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
04/03/2025
Locations: Flourish Research - Chicago, Chicago, Illinois
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895
Recruiting
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Register for Updates
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
04/03/2025
Locations: Great Lakes Clinical Trials, Chicago, Illinois
Conditions: Preclinical Alzheimer's Disease
Register for Updates
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Register for Updates
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113
Recruiting
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/03/2025
Locations: Northwestern Medicine Northwestern University, Winfield, Illinois
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: 89bio Clinical Study Site, Chicago, Illinois
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/03/2025
Locations: Research Site, Chicago, Illinois
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates